Edinburg, TX (April 15, 2021) – Patients undergoing Percutaneous Coronary Intervention (PCI) or stent placement, after a stroke or heart attack require treatment that would reduce the risk of ischemic events without increasing the risk of bleeding. In addition to Aspirin, Plavix (Clopidogrel) is the most commonly used drug for this purpose and has been shown to reduce the risk of acute cardiac events and mortality.  To be effective, Plavix has to be activated in the liver, but some people have defective process thus reducing its therapeutic value.

DHR Health and DHR Health Institute for Research & Development are working with Cipherome, Inc., to use their genetic technology to determine if a patient undergoing PCI for coronary events has an intact pathway to metabolize Plavix. Over 90 patients have already been recruited in this study and a total of 350 patients will be recruited in the next few months.   

Leadership from Cipherome, Inc., DHR Health and DHR Health Institute for Research and Development. From left to Right: Dr. Manish Singh, Chief Executive Officer, DHR Health; Dr. Jane Chiang, Chief Medical Officer, Cipherome, Inc; Dr. Yetunde O Kara Opaneye, Clinical Research Coordinator, DHR Health Institute for Research & Development; Jose Estabil, Chief Business Officer, Cipherome, Inc.; and Dr. Sohail Rao, President & Chief Executive Officer, DHR Health Institute for Research & Development.

As the first gene-based study to be piloted in the Rio Grande Valley, Dr. Jane Chiang, chief medical officer and Jose Estabil, chief business officer at Cipherome, Inc., visited with DHR Health and DHR Health Institute for Research and Development leadership to discuss the value of this personalized medicine study that began back in December of 2020.  Cipherome, Inc. preferred South Texas for this pilot project to better understand how the genetic differences in Hispanic/Latino patients relate to the effectiveness and safety of medications used to treat them.  

“The use of this technology will allow the physicians at DHR Health to predict how a patient undergoing PCI will respond to Plavix therapy based on that patient’s genetic makeup” said Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development.  “This study continues to build on the DHR Health vision to practice advanced medicine and to bring the most innovative clinical care to the community”.  

For more information on research studies, please contact Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development at (956) 362-2387 or visitwww.dhrresearch.org.

About DHR Health for Research & Development


DHR Health Institute for Research & Development, is a nonprofit organized under the Federal Internal Revenue Service Code 501(c)(3). As the only such entity in South Texas, DHR Health Institute for Research and Development leads the way for innovative, state-of-the-art clinical research in the Rio Grande Valley. To learn more visit our website at www.dhrresearch.org

About DHR Health


DHR Health was founded in 1997 to help over 1.4 million residents resolve limited health care access challenges in a community that lacked public and county hospitals. Today, it is a modern, 500+ bed full-service health system serving over 280,000 patients annually, with 5500+ employees, over 650 physicians and more than 1,400 nurses dedicated to offering a full-continuum of care in over 70 different specialties and subspecialties. DHR Health proudly boasts the best specialty care in the region, a 24/7 functioning level-one trauma center, a robust clinical research division, and developing graduate medical education programs. DHR Health has revolutionized the health care landscape of the Rio Grande Valley and continues to raise the standard of care and transform the health care delivery model for the benefit all local residents. To learn more, visit our website at www.dhrhealth.com.